DK1360202T3 - Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser - Google Patents
Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelserInfo
- Publication number
- DK1360202T3 DK1360202T3 DK02700079T DK02700079T DK1360202T3 DK 1360202 T3 DK1360202 T3 DK 1360202T3 DK 02700079 T DK02700079 T DK 02700079T DK 02700079 T DK02700079 T DK 02700079T DK 1360202 T3 DK1360202 T3 DK 1360202T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- glp
- glucagon
- peptide
- prolonged
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26927601P | 2001-02-16 | 2001-02-16 | |
PCT/CA2002/000175 WO2002066511A2 (en) | 2001-02-16 | 2002-02-15 | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1360202T3 true DK1360202T3 (da) | 2008-09-22 |
Family
ID=23026568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02700079T DK1360202T3 (da) | 2001-02-16 | 2002-02-15 | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser |
Country Status (14)
Country | Link |
---|---|
US (3) | US7112567B2 (pt) |
EP (2) | EP1360202B1 (pt) |
JP (4) | JP4280070B2 (pt) |
AP (1) | AP1886A (pt) |
AT (1) | ATE396202T1 (pt) |
AU (1) | AU2002233089B2 (pt) |
CA (1) | CA2436399A1 (pt) |
CY (1) | CY1108274T1 (pt) |
DE (1) | DE60226702D1 (pt) |
DK (1) | DK1360202T3 (pt) |
EA (1) | EA006160B1 (pt) |
ES (1) | ES2307718T3 (pt) |
PT (1) | PT1360202E (pt) |
WO (1) | WO2002066511A2 (pt) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
WO2000069911A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
DE60226702D1 (de) | 2001-02-16 | 2008-07-03 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
DK1412384T3 (da) * | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
JP2007524592A (ja) * | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
KR101308912B1 (ko) * | 2003-06-03 | 2013-09-23 | 노보 노르디스크 에이/에스 | 안정화된 약학적 펩티드 조성물 |
KR101243648B1 (ko) * | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
DE602005022239D1 (de) * | 2004-04-23 | 2010-08-19 | Conjuchem Biotechnologies Inc | Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten |
EP1789434B1 (en) * | 2004-08-31 | 2013-11-20 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
DK1809318T3 (da) | 2004-11-01 | 2013-09-08 | Nps Pharma Inc | Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet |
EP1817048B1 (en) * | 2004-11-12 | 2014-02-12 | Novo Nordisk A/S | Stable formulations of insulinoptropic peptides |
KR101200227B1 (ko) | 2005-05-04 | 2012-11-13 | 질랜드 파마 에이/에스 | 글루카곤 유사 펩티드-2(glp-2) 유사체 |
BRPI0617515A2 (pt) * | 2005-10-24 | 2011-07-26 | Centocor Inc | mimeticorpos, polipeptÍdeos, composiÇÕes, mÉtodos e usos de glp-2 |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
WO2008028117A2 (en) * | 2006-08-31 | 2008-03-06 | Centocor, Inc. | Glp-2 mimetibodies, polypeptides, compositions, methods and uses |
NZ576260A (en) * | 2006-11-08 | 2012-04-27 | Zealand Pharma As | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2 |
US20090099074A1 (en) * | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
WO2009043447A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP2231191A2 (en) * | 2007-12-11 | 2010-09-29 | ConjuChem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
EP2926825A1 (en) | 2008-06-27 | 2015-10-07 | Duke University | Therapeutic agents comprising elastin-like peptides |
EP2311486A1 (en) * | 2009-10-07 | 2011-04-20 | Nestec S.A. | GLP-2 for use in intestine and muscle recovery |
EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
WO2012028602A1 (en) * | 2010-08-30 | 2012-03-08 | Nycomed Gmbh | Solid phase synthesis of h(gly2)glp-2 |
KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
CA2872315A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
US9289507B2 (en) | 2012-05-17 | 2016-03-22 | Extend Biosciences, Inc. | Carriers for improved drug delivery |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
EP3220961B1 (en) | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
CN108473547A (zh) * | 2015-10-28 | 2018-08-31 | 塔夫茨大学 | 具有改良的蛋白质分解安定性的新颖多肽,以及制备与使用该新颖多肽的方法 |
BR112019000610A2 (pt) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | fator vii de coagulação de longa ação e métodos de produção do mesmo |
BR112019010624A2 (pt) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | agonistas duplos de glp-1/glp-2 acilados e composição |
HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
BR112020006189A2 (pt) * | 2017-09-28 | 2020-10-13 | Hanmi Pharm. Co., Ltd. | conjugado de peptídeo-2 tipo glucagon (glp-2), derivado de glp-2 que compreende uma sequência de aminoácidos e seu método se preparação, ácido nucleico isolado que codifica o derivado de glp-2, vetor de expressão recombinante que compreende o ácido nucleico, transformante que compreende o vetor de expressão recombinante, composição farmacêutica para prevenir ou tratar uma ou mais doenças selecionadas |
CN108395469A (zh) * | 2018-02-01 | 2018-08-14 | 滨海吉尔多肽有限公司 | 一种假脯氨酸二肽的合成方法 |
WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
EP3628683A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
EP3628682A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
WO2020165900A1 (en) | 2019-02-11 | 2020-08-20 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
IL291985A (en) | 2019-10-07 | 2022-06-01 | Kallyope Inc | gpr119 agonists |
US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
EP4172162A1 (en) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Ampk activators |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1160380A (en) * | 1966-12-22 | 1969-08-06 | Ford Motor Co | Vehicle Engine Arrangement. |
US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
DE3241416A1 (de) * | 1982-01-19 | 1983-07-28 | Josef Gartner & Co, 8883 Gundelfingen | Isolierverglasung |
US4462941A (en) | 1982-06-10 | 1984-07-31 | The Regents Of The University Of California | Dynorphin amide analogs |
DK608589D0 (da) | 1989-12-01 | 1989-12-01 | Holm Arne | Kemisk fremgangsmaade |
US5843440A (en) | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
US5612034A (en) | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
DE69226077T2 (de) | 1991-04-05 | 1998-12-03 | Genentech Inc | PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa |
DE4122210C2 (de) | 1991-07-04 | 1999-04-01 | Deutsches Krebsforsch | Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung |
KR950701818A (ko) | 1992-06-12 | 1995-05-17 | 원본미기재 | 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues) |
EP0602290B1 (en) | 1992-12-04 | 1999-08-25 | ConjuChem, Inc. | Antibody-conjugated Hepatitis B surface antigen and use thereof |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5580853A (en) | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US5496007A (en) * | 1994-05-13 | 1996-03-05 | Reece; Cecil L. | Device for holding out-sized documents |
CZ52397A3 (en) | 1994-08-26 | 1997-07-16 | Nancy M Lee | Analgesic method by dynorphin analogs being modified at n-end |
US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US6184201B1 (en) * | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
US5654276A (en) | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
CA2215152A1 (en) | 1996-01-12 | 1997-07-17 | Redcell Canada, Inc. | Cellular and serum protein anchors for diagnostic imaging |
US6277583B1 (en) | 1996-02-07 | 2001-08-21 | Conjuchem, Inc. | Affinity labeling libraries and applications thereof |
JP2000516912A (ja) | 1996-06-05 | 2000-12-19 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | エキセンジン類似体、それらの製造方法およびそれらを含有する製剤 |
US5840733A (en) | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
ES2319936T5 (es) | 1996-08-08 | 2013-06-24 | Amylin Pharmaceuticals, Inc. | Regulación de la motilidad gastrointestinal |
EP0929576A1 (en) * | 1996-08-30 | 1999-07-21 | Novo Nordisk A/S | Glp-2 derivatives |
WO1998011437A1 (en) | 1996-09-16 | 1998-03-19 | Conjuchem, Inc. | Affinity labeling libraries with tagged leaving groups |
WO1998024813A2 (en) * | 1996-12-06 | 1998-06-11 | Amgen Inc. | Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives |
US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
US6723530B1 (en) | 1997-02-05 | 2004-04-20 | Amylin Pharmaceuticals, Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
PT1019077E (pt) | 1997-08-08 | 2008-02-21 | Amylin Pharmaceuticals Inc | Novos compostos agonistas de exendina |
US6437092B1 (en) | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
ES2173641T3 (es) | 1997-11-07 | 2002-10-16 | Conjuchem Inc | Composicion de derivados opiaceos para la fabricacion de medicamentos. |
CA2628053A1 (en) | 1997-11-07 | 1999-05-20 | Conjuchem Biotechnologies Inc. | Affinity markers for human serum albumin |
EP1030688B1 (en) | 1997-11-12 | 2004-09-29 | Alza Corporation | Method for dermally administering polypeptides |
BR9814189A (pt) | 1997-11-14 | 2000-10-03 | Amylin Pharmaceuticals Inc | "compostos agonistas da exendina" |
EP1066314B1 (en) | 1997-11-14 | 2007-12-26 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
JP2002504527A (ja) | 1998-02-27 | 2002-02-12 | ノボ ノルディスク アクティーゼルスカブ | 部分的に組織化したミセル様凝集物を形成する25%を越えるヘリックス成分を有するglp−2誘導体 |
EP1056775B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
US6107489A (en) | 1998-03-17 | 2000-08-22 | Conjuchem, Inc. | Extended lifetimes in vivo renin inhibitors |
AU748496B2 (en) | 1998-03-23 | 2002-06-06 | Conjuchem, Inc. | Local delivery of long lasting therapeutic agents |
US20030170250A1 (en) | 1998-03-23 | 2003-09-11 | Ezrin Alan M. | Local delivery of long lasting therapeutic agents |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
US6440417B1 (en) | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
US6451974B1 (en) | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
DK1105409T3 (da) * | 1999-05-17 | 2006-07-03 | Conjuchem Inc | Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
CA2373252C (en) | 1999-05-17 | 2007-08-07 | Conjuchem Inc. | Long lasting anti-angiogenic peptides |
WO2000069911A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
US20040266673A1 (en) | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
EP1264840B1 (en) | 1999-05-17 | 2009-09-23 | ConjuChem Biotechnologies Inc. | Long lasting fusion peptide inhibitors of viral infection |
US7144854B1 (en) | 1999-09-10 | 2006-12-05 | Conjuchem, Inc. | Long lasting anti-angiogenic peptides |
DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
DE19926475A1 (de) | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
JP2003508501A (ja) | 1999-09-07 | 2003-03-04 | コンジュケム,インコーポレーテッド | 生物学的結合のための肺送達 |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
JP2004520395A (ja) | 2001-02-02 | 2004-07-08 | コンジュケム,インコーポレーテッド | 長期持続性成長ホルモン放出因子誘導体 |
DE60226702D1 (de) | 2001-02-16 | 2008-07-03 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
DE60229677D1 (de) | 2001-05-31 | 2008-12-11 | Conjuchem Biotechnologies Inc | Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion |
US6882816B2 (en) * | 2002-02-19 | 2005-04-19 | Matsushita Electric Industrial Co., Ltd. | Developing device with developer circulating path |
CA2488348A1 (en) | 2002-07-31 | 2004-02-05 | Conjuchem Inc. | Long lasting natriuretic peptide derivatives |
EP2085406A1 (en) | 2003-07-25 | 2009-08-05 | ConjuChem Biotechnologies Inc. | Long lasting insulin derivatives and methods thereof |
DE602005022239D1 (de) | 2004-04-23 | 2010-08-19 | Conjuchem Biotechnologies Inc | Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten |
US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
CA2634495A1 (en) | 2005-12-22 | 2007-06-28 | Conjuchem Biotechnologies Inc. | Process for the production of preformed conjugates of albumin and a therapeutic agent |
-
2002
- 2002-02-15 DE DE60226702T patent/DE60226702D1/de not_active Expired - Lifetime
- 2002-02-15 AT AT02700079T patent/ATE396202T1/de active
- 2002-02-15 AU AU2002233089A patent/AU2002233089B2/en not_active Ceased
- 2002-02-15 PT PT02700079T patent/PT1360202E/pt unknown
- 2002-02-15 EP EP02700079A patent/EP1360202B1/en not_active Expired - Lifetime
- 2002-02-15 US US10/203,808 patent/US7112567B2/en not_active Expired - Fee Related
- 2002-02-15 WO PCT/CA2002/000175 patent/WO2002066511A2/en active IP Right Grant
- 2002-02-15 EA EA200300857A patent/EA006160B1/ru not_active IP Right Cessation
- 2002-02-15 JP JP2002566224A patent/JP4280070B2/ja not_active Expired - Lifetime
- 2002-02-15 CA CA002436399A patent/CA2436399A1/en not_active Abandoned
- 2002-02-15 ES ES02700079T patent/ES2307718T3/es not_active Expired - Lifetime
- 2002-02-15 DK DK02700079T patent/DK1360202T3/da active
- 2002-02-15 EP EP08156596A patent/EP1980572A1/en not_active Withdrawn
- 2002-11-13 AP AP2005003310A patent/AP1886A/xx active
-
2005
- 2005-12-23 US US11/318,323 patent/US7737251B2/en not_active Expired - Fee Related
-
2008
- 2008-03-28 JP JP2008088237A patent/JP2008179652A/ja active Pending
- 2008-08-20 CY CY20081100886T patent/CY1108274T1/el unknown
- 2008-10-10 JP JP2008264644A patent/JP2009035568A/ja not_active Withdrawn
-
2009
- 2009-07-19 US US12/505,506 patent/US20090312259A1/en not_active Abandoned
-
2010
- 2010-03-03 JP JP2010046750A patent/JP2010150276A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CY1108274T1 (el) | 2014-02-12 |
DE60226702D1 (de) | 2008-07-03 |
WO2002066511A2 (en) | 2002-08-29 |
US20090312259A1 (en) | 2009-12-17 |
JP2010150276A (ja) | 2010-07-08 |
US20040248782A1 (en) | 2004-12-09 |
US7737251B2 (en) | 2010-06-15 |
ES2307718T3 (es) | 2008-12-01 |
AP2005003310A0 (en) | 2005-06-30 |
AP1886A (en) | 2008-09-20 |
US20060217304A1 (en) | 2006-09-28 |
EA200300857A1 (ru) | 2003-12-25 |
JP2004532819A (ja) | 2004-10-28 |
CA2436399A1 (en) | 2002-08-29 |
AU2002233089B2 (en) | 2005-12-22 |
JP2008179652A (ja) | 2008-08-07 |
JP2009035568A (ja) | 2009-02-19 |
EP1980572A1 (en) | 2008-10-15 |
ATE396202T1 (de) | 2008-06-15 |
JP4280070B2 (ja) | 2009-06-17 |
PT1360202E (pt) | 2008-09-01 |
US7112567B2 (en) | 2006-09-26 |
EP1360202B1 (en) | 2008-05-21 |
EP1360202A2 (en) | 2003-11-12 |
WO2002066511A3 (en) | 2003-03-06 |
EA006160B1 (ru) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1360202T3 (da) | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser | |
IS7032A (is) | 4(fenýl-píperasinýl-metýl)bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum | |
IS7863A (is) | 4 (fenýl-píperasínýl-metýl)bensamíðafleiður og notkun þeirra til að meðhöndla verk eða sjúkdóma í maga og görnum | |
DK1286668T3 (da) | Farmaceutiske kombinationer indeholdende tegaserod og omeprazol og deres anvendelse til behandling af gastrointestinale sygdomme | |
IS7185A (is) | Glúkagon-líkir-peptíð-1 hermar í mönnum og notkunþeirra við meðhöndlun sykursýki og skylds ástands | |
NO20040246L (no) | TACI'er- og BR3-polypeptider og anvendelser derav | |
IS7189A (is) | Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra | |
IS7864A (is) | 4(fenýl-píperasínýl-metýl)bensamíðafleiður og notkun þeirra til að meðhöndla verk eða sjúkdóma í maga og görnum | |
NO20044192L (no) | 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater | |
DE60232146D1 (de) | Bildanzeigeschirm und bildanzeigeeinheit | |
NO20033123D0 (no) | Terapeutisk hinnedannende sammensetning og behandlingsplan derav | |
IS7026A (is) | 4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum | |
EP1462455A4 (en) | NOVEL PEPTIDES AND THEIR USES AS MEDICAMENTS | |
NO20023448D0 (no) | Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin | |
DK1408949T3 (da) | Glycinbetain og dets brugområde for opfindelsen | |
IS7027A (is) | 4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum | |
IS7275A (is) | Samsetning fyrir hollegg og notkun á henni | |
AU2003278664A1 (en) | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | |
IS7025A (is) | 4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum | |
EP1379228A4 (en) | (Z) -STYRYLBENZYLSULPONES AND THEIR PHARMACEUTICAL APPLICATIONS | |
PL375034A1 (en) | Human serpin polypeptides | |
IS7024A (is) | 4-(fenýl-píperidín-4-ýlíden-metýl)-bensamíðafleiður og notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum | |
DK1357910T3 (da) | Fremgangsmåde til forebyggelse og behandling af smerter i de indre organer og mavetarmlidelser | |
IS7029A (is) | 4-(fenýl-(píperidín-4-ýl)-amínó)-bensamíðafleiðurog notkun þeirra til meðhöndlunar á sársauka, kvíða eða truflunum í maga og þörmum | |
GB0115780D0 (en) | Therapeutic molecules and uses thereof |